Vincristine, idarubicin, dexamethasone and thalidomide in scleromyxoedema

Acta Dermato-Venereologica

Volumn 89, Issue 6, 2009, Pages 631-635

  Laimer, Martin ^a   Namberger, Konrad ^a   Massone, Cesare ^b   Koller, Josef ^a   Emberger, Michael ^a   Pleyer, Lisa ^a   Hintner, Helmut ^a   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Chemotherapy; Mucinosis; Paraproteinaemia

Indexed keywords

DEXAMETHASONE; IDARUBICIN; IMMUNOGLOBULIN LAMBDA CHAIN; THALIDOMIDE; VINCRISTINE;

ADULT; ANAMNESIS; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIESIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PARAPROTEINEMIA; PERIPHERAL NEUROPATHY; PLASMA CELL; PRIORITY JOURNAL; REMISSION; SCLEROMYXEDEMA; SKIN BIOPSY; URINALYSIS;

ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; IDARUBICIN; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PARAPROTEINEMIAS; REMISSION INDUCTION; SCLEROMYXEDEMA; THALIDOMIDE; VINCRISTINE;

EID: 71949092857     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0731     Document Type: Article

References (33)

1. Gholam P, Hartmann M, Enk A. Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins. Br J Dermatol 2007; 157: 1058-1060. (Pubitemid 47583517)
2. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44: 273-281. (Pubitemid 32172190)
3. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol 2003; 42: 31-35.
4. Illa I, de la Torre C, Rojas-Garcia R, Altes A, Blesa R, Sierra J, et al. Steady remission of scleromyxedema 3 years after autologous stem cell transplantation: an in vivo and in vitro study. Blood 2006; 108: 773-774. (Pubitemid 44061387)
5. Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol 2006; 24: 493-497.
6. Majeski C, Taher M, Grewal P, Dytoc M, Lauzon G. Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema. J Cutan Med Surg 2005; 9: 99-104.
7. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 2008; 87: 10-20.
8. Lacy MQ, Hogan WJ, Gertz MA, Dispenzieri A, Rajkumar SV, Hayman S, et al. Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation. Arch Dermatol 2005; 141: 1277-1282. (Pubitemid 41498926)
9. Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum 2008; 38: 188-194.
10. Desai A, James W. Lichen myxedematosus. In: Lebwohl M, Heymann W, Berth-Jones J, Coulson I, editors. Treatment of skin disease: comprehensive therapeutic strategies. 2nd edn. Philadelphia: Elsevier Science; 2006, p. 343-344.
11. Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg 2006; 25: 100-104. (Pubitemid 44189887)
12. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995; 33: 37-43.
13. Rongioletti F, Rebora A. Worsening of lichen myxedematosus during interferon alfa-2a therapy for chronic active hepatitis C. J Am Acad Dermatol 1998; 38; 760-761. (Pubitemid 28213721)
14. Rongioletti F, Hazini A, Rebora A. Coma associated with scleromyxoedema and interferon alfa therapy. Full recovery after steroids and cyclophosphamide combined with plasmapheresis. Br J Dermatol 2001; 144: 1283-1284. (Pubitemid 34204240)
15. Glasmacher A, Goldschmidt H, Mezger J, Haferlach T, Schmidt-Wolf IG, Gieseler F. Oral idarubicin, dexamethasone and vincristine in the treatment of multiple myeloma: final analysis of a phase II trial. Haematologica 2004; 89: 371-373. (Pubitemid 38788430)
16. Cook G, Clark RE, Morris TCM, Robertson M, Lucie NP, Anderson S, et al. A randomized study (WOSMM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. Br J Haematol 2004; 126: 792-798. (Pubitemid 39273819)
17. Glasmacher A, Haferlach T, Gorschlüter M, Mezger J, Maintz C, Clemens MR, et al. Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma. Leukemia 1997; 11 Suppl 5: S22-S26.
18. Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 2004; 140: 277-280. (Pubitemid 38332478)
19. Sansbury JC, Cocuroccia B, Jorizzo JL, Gubinelli E, Gisondi P, Girolomoni G. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 2004; 51: 126-131. (Pubitemid 38887490)
20. Amini-Adle M, Thieulent N, Dalle S, Balme B, Thomas L. Scleromyxedema: successful treatment with thalidomide in two patients. Dermatology 2007; 214: 58-60. (Pubitemid 46033002)
21. Thyssen JP, Zachariae C, Menne T. Successful treatment of scleromyxedema using thalidomide. J Eur Acad Dermatol Venereol 2006; 20: 1396-1397. (Pubitemid 44614686)
22. Jacob SE, Fien S, Kerdel FA. Scleromyxedema, a positive effect with thalidomide. Dermatology 2006; 213: 150-152.
23. Martins A, Paiva Lopes MJ, Tavares Belo R, Rodrigues JC. Scleromyxedema - thalidomide therapy. J Eur Acad Dermatol Venereol 2008; 22: 622-624.
24. Rayson D, Lust JA, Duncan A, Su WP. Scleromyxedema: a complete response to prednisone. Mayo Clin Proc 1999; 74: 481-484.
25. Kreuter A, Altmeyer P. High-dose dexamethasone in scleromyxedema: report of 2 additional cases. J Am Acad Dermatol 2005; 53: 739-740. (Pubitemid 41399959)
26. Lin YC, Wang HC, Shen JL. Scleromyxedema: an experience using treatment with systemic corticosteroid and review of the published work. J Dermatol 2006; 33: 207-210.
27. Harris RB, Perry HO, Kyle RA, Winkelmann RK. Treatment of scleromyxedema with melphalan. Arch Dermatol 1979; 115: 295-299.
28. Bata-Csorgo Z, Husz S, Foldes M, Korom I, Molnar K, Morvay M, et al. Scleromyxedema. J Am Acad Dermatol 1999; 41: 343-346.
29. Milam CP, Cohen LE, Fenske NA, Ling NS. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol 1988; 19: 469-477.
30. Hisler BM, Savoy LB, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol 1991; 24: 854-857.
31. Righi A, Schiavon F, Jablonska S, Doria A, Blasczyk M, Rondinone R, et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 2002; 61: 59-61.
32. Donato ML, Feasel AM, Weber DM, Prieto VG, Giralt SA, Champlin RE, et al. Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 2006; 107: 463-466. (Pubitemid 43076365)
33. Tschen JA, Chang JR. Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 1999; 40: 303-307.